Mikala, a 30-year-old woman from Copenhagen, has battled bulimia for more than a decade, tracing its onset back to an emotionally turbulent period in her late teens. She initially turned to self-induced vomiting as a coping mechanism after discovering her boyfriend was unfaithful, describing the act as a source of fleeting relief amid profound distress. Despite seeking psychiatric help for depression early in her illness, the compulsive behavior persisted, accompanied by escalating physical health concerns including dental decay, heart strain, and episodes of dizziness triggered by exercise and low nutrition.
Her treatment journey included an extended hospital stay focused primarily on weight restoration, but Mikala grew disillusioned as she felt the emotional and psychological complexities of her condition were insufficiently addressed. “I felt betrayed,” she said, reflecting on the disconnect between her lived experience and the clinical approach. By 2024, bulimia had become a deeply ingrained part of her identity.
In a novel intervention, Mikala encountered an advertisement from a Danish research group called Virtu, recruiting participants for a clinical trial exploring virtual reality (VR) therapy for eating disorders. The program requires participants to externalize their disorder by creating digital avatars representing the disorder's "voice," engaging in guided dialogues within a virtual environment to confront and challenge the internal critical narrative commonly present in such conditions.
Initially skeptical, Mikala reconsidered after recognizing that her disorder did manifest as an intrusive inner voice, delivering persistent and harsh self-judgments about her appearance, behavior, and social interactions. These internal messages, which she described as bullying and illogical, significantly affected her self-esteem and daily functioning.
The VR therapy model draws on this recognition, allowing patients to personify and verbalize these internal voices in a controlled, therapeutic setting. Treatment sessions aim to empower individuals to dispute the critical narrative, potentially diminishing its power over their actions and emotions.
Experts involved in the research note that many people with eating disorders experience such a critical inner voice, which, while not a hallucination, plays a central role in maintaining the disorder. By externalizing this voice, clinicians hope to foster new coping strategies that are difficult to achieve through traditional approaches.
Mikala’s participation in this VR therapy trial represents a growing interest in innovative treatments that move beyond weight-focused care to address the psychological roots of eating disorders. Early impressions suggest that such immersive and interactive techniques may offer promise for individuals who have struggled with longstanding, treatment-resistant symptoms. The trial’s outcomes, due to be evaluated in the coming year, will provide more insight into the effectiveness of virtual reality as an adjunctive therapy for bulimia and related conditions.
